MedTrace Logo

Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.

NCT03721627 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-10-30

No results posted yet for this study

Summary

This prospective open label study is designed to screen all available Gaucher disease patients \[either on enzyme replacement therapy (ERT) or not\] for hepatitis C virus (HCV) infection. Furthermore to evaluate the safety and effectiveness of combined Sofosbuvir/Ledipasvir regimen given for 12 weeks in chronically infected patients aged 6-18 years.

Conditions

  • Gaucher Disease
  • HCV

Interventions

DRUG

Ledipasvir/Sofosbuvir

Direct acting anti HCV drugs

Sponsors & Collaborators

  • Mansoura University Children Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2019-04-30
Completion
2019-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03721627 on ClinicalTrials.gov